Sponsoring and exhibiting at DDL 2026
DCA is sponsoring and exhibiting at this year’s Drug Delivery to the Lungs conference (DDL2026) in Edinburgh, Scotland, from 9th to 11th of December.
Widely recognised as the premier international conference and exhibition dedicated to pulmonary and nasal drug delivery, DDL2026 offers a rich three-day scientific lecture programme, an array of carefully selected keynote presentations, a poster exhibition and industry exhibitor demonstrations. Now in its 37th year, DDL attracts more than 1000 attendees from around the world.
Link to DDL website: https://ddl-conference.com/
We look forward to seeing you there!
Join us at stand #148
If you are planning to attend, please join Rob Veasey and James Mitchell at our stand (#148) to catch up and to discuss how our exceptional, multidisciplinary development team can support your device projects.
If you would like to arrange a specific time to meet, please contact medical@dca-design.com
A wealth of experience at DCA
With a wealth of experience gained developing leading originator drug delivery devices for global markets as well as generic devices, DCA’s work includes:
- Dry powder inhalers for asthma, COPD and inhaled insulin
- Pressurised metered dose inhalers
- Breath actuated inhalers
- Soft mist inhalers
- Intranasal delivery devices
- Dose counters and indicators
- Regimen assistance/assurance devices
- Connected and electro-mechanical devices
- Design for sustainability
- Due diligence and device selection
Our portfolio encompasses mass-market drug delivery devices that are manufactured in multi-billions, as well as lower volume devices targeting specific user populations and regional market needs. Alongside device design, we provide comprehensive support for industrialisation and create highly effective instructions and product packaging solutions.
Please visit our virtual exhibition for DDL
